Tetra Bio-Pharma Overview
- Year Founded
-
2007
- Status
-
Public
- Employees
-
39
- Stock Symbol
-
TBPMQ
- Investments
-
8
Tetra Bio-Pharma General Information
Description
Tetra Bio Pharma Inc is a biopharmaceutical leader in cannabinoid-based drug. It discovers and develops clinical programs aimed at bringing novel prescription drugs and treatments to patients and their healthcare providers. The company with its subsidiaries engaged in the development of an growing pipeline of Bio Pharmaceuticals and Veterinary Products containing cannabinoids. Tetra Bio-Pharma is focused on providing rigorous scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators, physicians and insurance companies.
Contact Information
Website
tetrabiosciences.comCorporate Office
- 2316 Saint Joseph Boulevard
- Orleans, Ontario K1C 1E8
- Canada
Corporate Office
- 2316 Saint Joseph Boulevard
- Orleans, Ontario K1C 1E8
- Canada
Tetra Bio-Pharma Stock Performance
As of 19-Jan-2024, Tetra Bio-Pharma’s current market cap is $84.7K.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $84.7K | 284K | -$0.06 |
Tetra Bio-Pharma Financials Summary
As of 31-Aug-2022, Tetra Bio-Pharma has a trailing 12-month revenue of null.
|
In Thousands, USD |
TTM 31-Aug-2022 | FY 2021 30-Nov-2021 | FY 2020 30-Nov-2020 | FY 2019 30-Nov-2019 |
|---|---|---|---|---|
| EV | 19,727 | 64,932 | 31,703 | 55,124 |
| Revenue | 0 | 0 | 0 | 0 |
| EBITDA | (30,213) | (40,078) | (15,775) | (9,885) |
| Net Income | (30,653) | (41,594) | (19,686) | (11,494) |
| Total Assets | 2,306 | 5,926 | 22,595 | 21,497 |
| Total Debt | 1,268 | 2,442 | 1,540 | 0 |
Tetra Bio-Pharma Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Tetra Bio-Pharma Comparisons
Industry
Financing
Details
Tetra Bio-Pharma Competitors (6)
One of Tetra Bio-Pharma’s 6 competitors is Roche, a Corporation company based in Basel, Switzerland.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Roche | Corporation | Basel, Switzerland | ||||
| Revive Therapeutics | Corporation | Toronto, Canada | ||||
| Cipla | Corporation | Mumbai, India | ||||
| Repare Therapeutics | Formerly VC-backed | Saint-Laurent, Canada | ||||
| Quantum BioPharma | Corporation | Toronto, Canada |
Tetra Bio-Pharma Patents
Tetra Bio-Pharma Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2022133612-A1 | Parenteral cannabinoid formulations and uses thereof | Inactive | 24-Dec-2020 | ||
| US-12129227-B2 | Methods, processes, and compositions for improved preparation of hu308 and hu433 | Active | 24-Sep-2020 | ||
| US-20230271908-A1 | Methods, processes, and compositions for improved preparation of hu308 and hu433 | Active | 24-Sep-2020 | ||
| WO-2022061461-A1 | Methods, processes, and compositions for improved preparation of hu308 and hu433 | Inactive | 24-Sep-2020 | ||
| AU-2019409889-A1 | Cannabis compositions and methods | Inactive | 18-Dec-2018 | A61K31/658 |
Tetra Bio-Pharma Signals
Tetra Bio-Pharma Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Tetra Bio-Pharma Investments & Acquisitions (8)
Tetra Bio-Pharma’s most recent deal was a Corporate with TALLC (Drug Discovery). The deal was made on 03-Jun-2020.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| TALLC (Drug Discovery) | 03-Jun-2020 | Corporate | Drug Discovery | ||
| CB2 Therapeutics | 21-Aug-2019 | Joint Venture | Drug Discovery | ||
| Panag Pharma | 01-May-2019 | Merger/Acquisition | Drug Discovery | ||
| Joint Venture (Tetra Bio-Pharma and Altus Formulation) | 29-Apr-2019 | Joint Venture | Drug Delivery | ||
| Phytopain Pharma | 19-Mar-2018 | Secondary Transaction - Private | Other Pharmaceuticals and Biotechnology |
Tetra Bio-Pharma ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Precious Metals
Industry
Rank
Percentile
Gold
Subindustry
Rank
Percentile
Tetra Bio-Pharma Exits (2)
Tetra Bio-Pharma’s most recent exit was on 22-Jun-2016 from Holizen. The exit was categorized as .
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| Holizen | 22-Jun-2016 | Completed |
|
||
| Export Hydro | 06-Nov-2015 | Merger/Acquisition | Completed |
Tetra Bio-Pharma Affiliates
Subsidiaries (1)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Targeted Pharmaceuticals | Marlborough, MA | 2018 |
Tetra Bio-Pharma FAQs
-
When was Tetra Bio-Pharma founded?
Tetra Bio-Pharma was founded in 2007.
-
Where is Tetra Bio-Pharma headquartered?
Tetra Bio-Pharma is headquartered in Orleans, Canada.
-
What is the size of Tetra Bio-Pharma?
Tetra Bio-Pharma has 39 total employees.
-
What industry is Tetra Bio-Pharma in?
Tetra Bio-Pharma’s primary industry is Specialty Retail.
-
Is Tetra Bio-Pharma a private or public company?
Tetra Bio-Pharma is a Public company.
-
What is Tetra Bio-Pharma’s stock symbol?
The ticker symbol for Tetra Bio-Pharma is TBPMQ.
-
What is the current market cap of Tetra Bio-Pharma?
The current market capitalization of Tetra Bio-Pharma is $84.7K.
-
Who are Tetra Bio-Pharma’s competitors?
Roche, Revive Therapeutics, Cipla, Repare Therapeutics, and Quantum BioPharma are some of the 6 competitors of Tetra Bio-Pharma.
-
What is Tetra Bio-Pharma’s annual earnings per share (EPS)?
Tetra Bio-Pharma’s EPS for 12 months was -$0.06.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process